Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03310580 · ClinicalTrials.gov registry record · Phase 2
Study of Netarsudil Ophthalmic Solution in Japanese/Japanese-American Subjects With Open-angle Glaucoma or Ocular Hypertension
A Phase 2 study of Primary Open Angle Glaucoma or Ocular Hypertension, sponsored by Aerie Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
- 20
- Study locations
NCT03310580 is a Phase 2 study of Primary Open Angle Glaucoma or Ocular Hypertension that has completed, run by Aerie Pharmaceuticals. The registered enrollment target is 42 participants, below the 50-participant average among 3 other Primary Open Angle Glaucoma or Ocular Hypertension trials with a reported enrollment target (16% lower). The trial reports 20 study locations across 5 states.
The verdict
NCT03310580, a Phase 2 study of Primary Open Angle Glaucoma or Ocular Hypertension, has completed, sponsored by Aerie Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
- 20
- Study locations
Study Summary
To test the safety and effectiveness of AR-13324 0.02% and 0.04% ophthalmic solution relative to placebo in Japanese/Japanese-American subjects with open-angle glaucoma or ocular hypertension in US.
Conditions Studied
Interventions
- DRUG AR-13324 Ophthalmic Solution 0.02%
- DRUG AR-13324 Ophthalmic Solution 0.04%
- DRUG AR-13324 Ophthalmic Solution Placebo
Study Locations (20)
California
- Milton M. Hom, OD FAAO FACAAISc - Azusa
- Havana Research Institute - Burbank
- Global Research Management - Glendale
- Southern California Eye Physicians & Surgeons - Los Alamitos
- East West Eye Institute - Los Angeles
- USC Roski Eye Institute University of Souther California - Los Angeles
- Global Research Foundation - Los Angeles
- The Eye Research Foundation - Newport Beach
- Southern California Eye Physicians Surgeons - Pasadena
- North Bay Eye Associates Inc. - Petaluma
- Martel Eye - Rancho Cordova
- University of California - San Diego
- AdvanceMed Clinical Research - San Diego
- Glaucoma Center of San Francisco - San Francisco
- Samsum Clinic - Santa Barbara
Arizona
- Arizona Eye Center - Chandler
- Arizona Glaucoma Specialists - Phoenix
Colorado
- MCB Clinical Research Centers LLC - Colorado Springs
Georgia
- Clayton Eye Clinical Research, LLC - Morrow
Hawaii
- Jenkins Eye Care - Honolulu
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2017-11-15 |
| Est. Completion | 2018-10-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03310580
The ClinicalTrials.gov registry entry for NCT03310580 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 50-participant average among 3 other Primary Open Angle Glaucoma or Ocular Hypertension trials with a reported enrollment target (16% lower). The listed sponsor is Aerie Pharmaceuticals, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Primary Open Angle Glaucoma or Ocular Hypertension appearing as the primary indexed condition, and to 3 interventions - of which AR-13324 Ophthalmic Solution 0.02% is the first listed.
NCT03310580 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Arizona, Colorado.
Frequently Asked Questions
What is clinical trial NCT03310580 about?
NCT03310580 is a clinical study titled "Study of Netarsudil Ophthalmic Solution in Japanese/Japanese-American Subjects With Open-angle Glaucoma or Ocular Hypertension". To test the safety and effectiveness of AR-13324 0.02% and 0.04% ophthalmic solution relative to placebo in Japanese/Japanese-American subjects with open-angle glaucoma or ocular hypertension in US.
What is the current status of trial NCT03310580?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2017-11-15. Estimated completion is 2018-10-25.
What conditions does trial NCT03310580 study?
This clinical trial studies the following conditions: Primary Open Angle Glaucoma or Ocular Hypertension.
What interventions are being tested in trial NCT03310580?
The interventions under investigation include: AR-13324 Ophthalmic Solution 0.02% (DRUG), AR-13324 Ophthalmic Solution 0.04% (DRUG), AR-13324 Ophthalmic Solution Placebo (DRUG).
Who is sponsoring clinical trial NCT03310580?
This trial is sponsored by Aerie Pharmaceuticals, which has 32 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03310580 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Georgia, Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Open Angle Glaucoma or Ocular Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Netarsudil Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
COMPLETED · Phase 2
-
A Prospective Study on the Efficacy of Direct Selective Laser Trabeculoplasty (DSLT) in Achieving >20% Intraocular Pressure (IOP) Reduction Without Medications at 6 Months in Naive, Untreated Glaucoma Patients
RECRUITING
-
Effect of Rhopressa on Intraocular Pressure (IOP) in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Post-SLT
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.